Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04FXY
|
|||
| Former ID |
DIB010026
|
|||
| Drug Name |
SMT-19969
|
|||
| Synonyms |
Small-molecule antibacterial agents (Clostridium difficile infection), Summit
Click to Show/Hide
|
|||
| Indication | C. difficile infection [ICD-11: 1A04; ICD-10: A00-B99] | Phase 3 | [1] | |
| Company |
Summit Corp plc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H16N6
|
|||
| Canonical SMILES |
C1=CC2=C(C=C1C3=CC4=C(C=C3)N=C(N4)C5=CC=NC=C5)NC(=N2)C6=CC=NC=C6
|
|||
| InChI |
1S/C24H16N6/c1-3-19-21(29-23(27-19)15-5-9-25-10-6-15)13-17(1)18-2-4-20-22(14-18)30-24(28-20)16-7-11-26-12-8-16/h1-14H,(H,27,29)(H,28,30)
|
|||
| InChIKey |
UHQFBTAJFNVZIV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 308362-25-6
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03595566) To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection (Ri-CoDIFy 2). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.